Once-Weekly Insulin Icodec Versus Daily Basal Insulin in Type 1 and Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis Stratified by Prior Insulin Treatment
This updated systematic review and meta-analysis demonstrates that once-weekly insulin icodec offers modestly superior glycemic control and time-in-range compared to daily basal insulin in adults with type 2 diabetes, particularly those who are new to insulin, while maintaining comparable efficacy but significantly higher hypoglycemia risk in type 1 diabetes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of people living with diabetes, the management of blood sugar relies on a daily ritual: a subcutaneous injection of basal insulin. This hormone acts as a steady background current, keeping glucose levels stable between meals and during sleep. While modern insulin analogues have made this therapy safer and more effective, the requirement to inject every single day remains a significant hurdle. The sheer repetition can wear down a patient's resolve, leading to missed doses and, consequently, poorer health outcomes. Scientists have long sought a way to maintain this steady protection while reducing the frequency of these injections, hoping to replace the daily needle with a weekly one. This would transform a year of 365 injections into just 52, a change that could fundamentally alter the daily experience of living with the disease.
The search for this solution has led to the development of insulin icodec, a new type of basal insulin engineered to stay active in the body for a full week. Researchers have now conducted a comprehensive review of all available clinical trials to determine how well this once-weekly option works compared to the standard daily injections. They looked at data from nine different studies involving thousands of adults with both type 1 and type 2 diabetes. The goal was to see if the convenience of a weekly shot came at the cost of safety or effectiveness. The findings reveal a story of two different outcomes depending on the type of diabetes, offering a clear picture of where this new treatment shines and where it requires caution.
In people with type 2 diabetes, the once-weekly insulin proved to be a modest but meaningful improvement over daily injections. When researchers combined the results from eight large trials, they found that patients using the weekly shot saw a slightly greater drop in their average blood sugar levels over time compared to those sticking with daily shots. This improvement was most noticeable in people who had never used insulin before; for them, the simpler weekly schedule seemed to help them reach their target blood sugar levels more consistently. These patients also spent more time with their glucose levels in the healthy range. However, this benefit came with a small trade-off: patients on the weekly insulin gained a little more weight, roughly equivalent to a couple of pounds on average.
Safety was a major focus of the review, particularly regarding low blood sugar, a dangerous side effect of insulin therapy. In the type 2 diabetes trials, the weekly insulin showed a slight tendency to cause more episodes of significant low blood sugar than the daily version, but the data did not reach a level of certainty that would declare it a definitive risk. The increase was small and varied across the different studies. For the vast majority of patients with type 2 diabetes, the balance of benefits and risks appeared favorable, suggesting that the weekly option is a viable way to reduce the burden of treatment without sacrificing control.
The story changes significantly when looking at type 1 diabetes. In the single large trial dedicated to this group, the weekly insulin worked just as well as the daily standard at lowering blood sugar, but the safety profile was different. Patients with type 1 diabetes who switched to the weekly shot experienced nearly twice as many episodes of severe low blood sugar compared to those who stayed on the daily regimen. This difference was clear and statistically robust. The researchers explain that this is likely because people with type 1 diabetes have no natural insulin production to buffer their bodies against the peaks and valleys of a once-weekly drug. Without that internal safety net, the fluctuating levels of a weekly injection can lead to more frequent and dangerous drops in blood sugar.
These results have already influenced how this medicine is viewed by regulators around the world. While the drug has been approved for use in type 2 diabetes in several countries, including the United States, its approval for type 1 diabetes has been blocked or restricted due to the heightened risk of low blood sugar. The review confirms that the drug is not a one-size-fits-all solution. For the millions of adults with type 2 diabetes, especially those just starting insulin, the weekly shot offers a compelling way to simplify their lives and improve their control. For those with type 1 diabetes, however, the daily rhythm of injection remains the safer choice, as the convenience of a weekly dose introduces a risk that outweighs the benefit for this specific group. The science here does not offer a magic bullet, but it does provide a clear map for doctors and patients to navigate the complex landscape of modern diabetes care.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.